Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22529265

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2012 Jun 10
First author
Aghajanian C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2012 May 15;9(6):305. doi: 10.1038/nrclinonc.2012.84.
    note
    Source null
    related pmid
    22585001
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2013 Jan 1;31(1):166-7. doi: 10.1200/JCO.2012.44.6237.
    note
    Source null
    related pmid
    23169499
    relationship
    Comment in

Authors and identifiers

  1. name
    Aghajanian C
    type
    Author
  2. name
    Blank SV
    type
    Author
  3. name
    Goff BA
    type
    Author
  4. name
    Judson PL
    type
    Author
  5. name
    Teneriello MG
    type
    Author
  6. name
    Husain A
    type
    Author
  7. name
    Sovak MA
    type
    Author
  8. name
    Yi J
    type
    Author
  9. name
    Nycum LR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Aghajanian C
    type
    Author
  2. name
    Blank SV
    type
    Author
  3. name
    Goff BA
    type
    Author
  4. name
    Judson PL
    type
    Author
  5. name
    Teneriello MG
    type
    Author
  6. name
    Husain A
    type
    Author
  7. name
    Sovak MA
    type
    Author
  8. name
    Yi J
    type
    Author
  9. name
    Nycum LR
    type
    Author
bibliography ids
  1. nci-bib-63372ab4f956986eebbc1a11
book metadata
content sha256
706a6e0decc099077f248cceded8eb61b2d4b15c3b714791e6bc6c482632d271
document type
citation
dois
  1. 10.1200/JCO.2012.42.0505
electronic publication date
display
2012 Apr 23
precision
day
year
2012
evidence scope
bibliographic_metadata_only
id
pubmed:22529265
immutable id
pubmed:22529265@706a6e0decc099077f248cceded8eb61b2d4b15c3b714791e6bc6c482632d271
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
17
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2039-45
volume
30
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2012 May 15;9(6):305. doi: 10.1038/nrclinonc.2012.84.
    note
    Source null
    related pmid
    22585001
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2013 Jan 1;31(1):166-7. doi: 10.1200/JCO.2012.44.6237.
    note
    Source null
    related pmid
    23169499
    relationship
    Comment in
outcomes validated
false
pmid
22529265
provenance
batch id
c95be1d0b8cf19942816
provider
NCBI PubMed ESummary
record sha256
7c30e0ecb386b4f77741427908962821330d3d7eef4e704ed3f45482252ae39b
response sha256
a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
retrieved at
2026-09-09T23:46:47.691937+00:00
publication date
display
2012 Jun 10
precision
day
year
2012
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/22529265/
title
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Preserved source evidence · Not medical advice